Home
Live Updates
Novel PCSK9 Inhibitor Reduced LDL by 50% : comparemela.com
Novel PCSK9 Inhibitor Reduced LDL by 50%
Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.
Related Keywords
South Africa ,
United States ,
Johannesburg ,
Gauteng ,
American ,
Eric Klug ,
American College Of Cardiology ,
Division Of Cardiology ,
University Of The Witwatersrand ,
European Society Of Cardiology ,
Prevention Of Cardiovascular Disease Council ,
Virginia Commonwealth University School Of Pharmacy ,
American Heart Association ,
Drug Administration ,
American College ,
Scientific Session ,
European Society ,
Virginia Commonwealth University School ,
Cardiovascular Disease Council ,
comparemela.com © 2020. All Rights Reserved.